Ségolène Martin is the CEO and co-founder of Kantify, a TechBio company specializing in Artificial Intelligence to enhance drug discovery, notably with the recently launched Sapian technology. In addition to leading Kantify, Ségolène serves as Vice-Chair and Advisory Board Member of lifetech.brussels, a HealthTech cluster in Brussels, and participates as a Working Group Member on Innovation and Commercialization for the Global Partnership on Artificial Intelligence. Ségolène is also a member of the European Commission's Digital SME Focus Group on AI and previously held the role of Ambassador for Women in AI in Belgium. Other notable positions include board memberships at BeCode.org and cluster software.brussels, as well as a Chief Marketing Officer role at Meetsies. Ségolène's early career involved significant contributions to CEN and CENELEC, focusing on technical policy and innovation strategies, and coordination of the Automotive Crisis Intergroup at the Committee of the Regions. Ségolène holds an MBA from The Open University and advanced training in WTO agreements, along with a master's degree in European Public Affairs from Sciences Po Strasbourg.